Prognostic Significance of Preimmunotherapy Serum CA27.29 (MUC-1) Mucin Level After Active Specific Immunotherapy of Metastatic Adenocarcinoma Patients

MacLean, G D; Reddish, M A; Longenecker, B. M.

doi:10.1097/00002371-199701000-00008

Cited by 48 publications

(26 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One can hypothesize that some cellular clones of the primary tumour able to secrete these tumour markers also developed a high metastatic potential, the tumour marker being involved in the process or not. Moreover, recent studies reported that natural antibodies (Hilgers, 1998) and active specific immunotherapy against tumour markers belonging to the group of epithelial mucins were protective against metastatic progression, patients with a high serum level of mucin before immunotherapy showing a poor prognosis (Maclean et al, 1997). These observations suggest that, beyond its diagnostic interest, pleural assay of some tumour markers could have some prognostic value.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of seven tumour markers in pleural fluid for the diagnosis of malignant effusions

et al. 1999

View full text Add to dashboard Cite

Summary Carcinoembryonic antigen (CEA), carbohydrate antigens , cytokeratin 19 fragments (CYFRA 21-1), neuron-specific enolase (NSE) and squamous cell carcinoma antigen (SCC) were evaluated in pleural fluid for the diagnosis of malignant effusions. With a specificity of 99%, determined in a series of 121 benign effusions, the best individual diagnostic sensitivities in the whole series of 215 malignant effusions or in the subgroup of adenocarcinomas were observed with CEA, CA 15-3 and CA 72-4. As expected, a high sensitivity was obtained with SCC in squamous cell carcinomas and with NSE in small-cell lung carcinomas. CYFRA and/or CA 15-3 were frequently increased in mesotheliomas. Discriminant analysis showed that the optimal combination for diagnosis of nonlymphomatous malignant effusions was CEA + CA 15-3 + CYFRA + NSE: sensitivity of 94.4% with an overall specificity of 95%. In malignant effusions with a negative cytology, 83.9% were diagnosed using this association. The association CYFRA + NSE + SCC was able to discriminate adenocarcinomas from small-cell lung cancers. Regarding their sensitivity and their complementarity, CEA, CA 15-3, CYFRA 21-1, NSE and SCC appear to be very useful to improve the diagnosis of malignant pleural effusions.

show abstract

Section: Discussionmentioning

confidence: 99%

Evaluation of seven tumour markers in pleural fluid for the diagnosis of malignant effusions

et al. 1999

View full text Add to dashboard Cite

show abstract

“…and the elevated levels of serum MUC1 are always associated with poor survival. 42,43 The determination of the level of MUC1 protein in the serum has been exploited as a measure of tumor burden and changing levels, as a reflection of the response to therapy. 44,45 …”

Section: Expression Of Muc1 Protein In Normal and In Cancermentioning

confidence: 99%

MUC1: A target molecule for cancer therapy

Singh

Bandyopadhyay²

2007

Cancer Biology & Therapy

153

142

View full text Add to dashboard Cite

“…Significant data now exists that induced IgG antibody responses to the STn epitope can be clinically beneficial to patients with breast, ovarian and colorectal cancers [20,21]. In these same immunotherapy studies there was a significant negative correlation between the serum levels of MUC1 and the patient's immune response [22,23]. Recently, MUC1 mucin was shown to induce apoptosis of activated T cells [24].…”

Section: Discussionmentioning

confidence: 99%

Analysis of the Role of Type 1 Core O-Glycans in the Binding of Anti-MUC1 Antibodies by Cytofluorometry and Synthetic Peptide/Glycopeptide Binding Inhibition Studies

Ma¹,

Mr²,

Rr³

et al. 1998

Tumor Biol

Self Cite

View full text Add to dashboard Cite

A panel of 56 MAbs submitted to the ISOBM TD-4 (MUC1) Workshop were analysed in two systems. These systems were designed to screen for peptide type 1 core O-glycan-related reactivities. Using synthetic MUC1 mucin-related peptides and glycopeptides, the panel of MAbs were tested for relative binding affinities to type 1 core O-glycan-substituted MUC1 structures. These studies utilized a competitive binding format with a native human adenocarcinoma-derived mucin as a solid phase. This system allows for analysis of the type 1 core glycoform subspecificity of each MAb. The second approach taken in parallel, utilized MCF-7 (BrCa) and OVCAR (OVCa) cell lines which were grown in the presence or absence of phenyl-N-acetylgalactosaminide (p-gal), a blocker of mucin O-linked glycosylation. These cells were analysed by FACS to examine the role these same glycan substitutions play with regard to either the diagnostic or therapeutic application of these MAbs. By FACS analysis there was a consistent increased ‘epitope exposure’ for peptide-specific MAbs binding in the presence of p-gal. In addition, a single MAb (TD-4 #150) is interpreted to react with a type 1 core O-glycan, probably with Tn, TF or STn specificity.

show abstract

Prognostic Significance of Preimmunotherapy Serum CA27.29 (MUC-1) Mucin Level After Active Specific Immunotherapy of Metastatic Adenocarcinoma Patients

Cited by 48 publications

References 0 publications

Evaluation of seven tumour markers in pleural fluid for the diagnosis of malignant effusions

Evaluation of seven tumour markers in pleural fluid for the diagnosis of malignant effusions

MUC1: A target molecule for cancer therapy

Analysis of the Role of Type 1 Core O-Glycans in the Binding of Anti-MUC1 Antibodies by Cytofluorometry and Synthetic Peptide/Glycopeptide Binding Inhibition Studies

Contact Info

Product

Resources

About